Accuracy in suspicious lung infiltrations

We read with interest the paper by Targowski et al.1 Suspicious lung infiltrations such as malignant tumours are always difficult to diagnose in clinical practice. Transthoracic fine needle biopsy (TFNB) may be a useful procedure despite a high risk of false negative results. To improve the accuracy of the technique, telomerase activity in combination with TFNB was investigated in the study by Targowski et al.

We suggest that alternative options such as positron tomography scanning (CT-PET) should be evaluated, which may provide better imaging quality and accurate guidance for performing TFNB, increasing the accuracy of lung cancer diagnosis.

In the Continuing Observation of Smoking Subjects (COSMOS) study by Veronesi et al.,2 CT-PET had a sensitivity of 100% in the diagnosis of solid pulmonary nodules of 10 mm and more. In our study the mean size of suspected lesions (described at the beginning of the Results section) was 2.4 cm (95% CI 2.2 to 2.5), which was comparable to data in the study by Veronesi et al. (2.5 cm, range 0.6–6 cm), but the indication for TFNB was not only restricted to solid nodules. The sensitivity, specificity and accuracy of cytological and telomerase activity examinations in our study were adequate (89.3%, 96.9%, 90%, respectively) and was similar to the overall results achieved by Veronesi et al. (88%, 93% and 91%, respectively). The diagnostic value of telomerase activity assessments in pulmonary tumours is only one of many benefits. Data show that telomerase activity in material derived from pulmonary nodules is also a prognostic factor for survival and could be a target for antitumour treatment.

T Targowski, K Jahnz-Różyk
Department of Internal Medicine, Pneumonology and Allergology, Military Institute of Health Service, Warsaw, Poland

Correspondence to: Professor T Targowski, Department of Internal Medicine, Pneumonology and Allergology, Military Institute of Health Service, Warsaw, Poland
targowski.tomasz_x1@wp.pl

REFERENCES

Dysfunctional breathing in patients with asthma

We recognise and applaud the efforts of Holloway and West3 and are encouraged by their findings. We agree that further investigation is warranted but that greater scientific methodology needs to be applied. Hyperventilation appears to be the only form of dysfunctional breathing that most physicians recognise yet even within this label, acute and chronic hyperventilation are physiologically distinct.4 Efforts must be made to further elucidate the nature of dysfunctional breathing in its many forms5 and direct appropriate therapy towards appropriate patients. It is a reasonable assumption that breathing retraining will be efficacious only in those patients where dysfunctional breathing exists. This lends support to the positive results of Holloway and West,3 given the unselected nature of the cohort of subjects recruited. It is broadly surprising that many trials of breathing retraining in unselected asthmatics prove equivocal. We liken this approach to a trial of thrombolytic therapy in unselected chest pain patients.

As a sub-note, we would guard against making assumptions on the basis of a reduction in Nijmegen scores. The Nijmegen questionnaire has only ever been validated in primary hyperventilation and even then the gold standard was physician interpreted typical symptoms.6 It was only described as a threshold value for the diagnosis of hyperventilation and there is no evidence that there is a graded correlation between Nijmegen scores and symptom severity. The domains within the questionnaire overlap with asthma symptoms. We have found it not to be predictive of capnography in patients with severe asthma. Since there is a trend towards improved spirometric values in the study group of Holloway and West,3 we would suggest caution in interpreting a reduction in Nijmegen scores as a positive signal of reduced dysfunctional breathing.

C O Prys-Picard, R Niven
1 UTMB Galveston, Texas, USA; 2 North West Lung Centre, Manchester, UK

Correspondence to: Dr C O Prys-Picard, UTMB Galveston, 310 University Boulevard, Galveston, Texas 77550-0561, USA; copryspi@utmb.edu

Competing interests: None.

Thorax 2008;63:568. doi:10.1136/thx.2007.093989

REFERENCES

Use of long-acting β2 agonists in arginine-16 homozygous patients with asthma

We read with interest the study by Palmer and colleagues.1 Their findings suggest that patients who are Arg/Arg homozygous at position 16 of the β2 adrenoceptor may be at increased risk of asthma exacerbations.